Administrador

On a recent study that analyzed patients between 17 and 93 years of age (N = 1592), who were participants in the ECOG-ACRIN trials, the influence of the most common monosomies (5, 7, and 17) within monosomal karyotype (MK+)/complex karyotype (CK+) acute myeloid leukemia (AML) was investigated. Most MK+ patients (93%) were found to be […]

A group of researchers investigated if detection of circulating tumor DNA (ctDNA) after resection of colorectal cancer (CRC) identifies the patients with the highest risk of relapse, and furthermore, whether longitudinal ctDNA analysis allows early detection of relapse and informs about response to intervention. During this longitudinal cohort study massively parallel sequencing (NGS)  was used

The cell cycle–related genes AURORA A and Forkhead box M1 (FOXM1) are overexpressed in melanoma. AURKA overexpression was associated with poor prognosis in three independent cohorts of melanoma patients and correlates with the presence of genomic amplification of AURKA locus and BRAFV600E mutation. Activated MAPK-ERK signalling pathway mediates robust AURKA promoter activation, thereby knockdown of

Next-generation deep sequencing was used to determine the mutational status of hotspot regions in 340 adults and children with B-cell precursor ALL. The frequency of adult vs child mutations was significantly higher (20.2% vs 7.6%). The most commonly mutated genes were TP53, JAK2, CRLF2, PAX5, LEF1, and IL7R, respectively. Significantly lower overall survival and event-free

Patients with previously untreated BRAF V600E/K–mutant metastatic melanoma were enrolled in this double-blinded phase III study of combination dabrafenib and trametinib (n = 211) vs dabrafenib plus placebo monotherapy (n = 212). Here, the authors here look at the efficacy and safety data following ≥36 months of follow-up. The 3-year progression-free survival was 22% in

Blockade of the epidermal growth factor receptor (EGFR) with cetuximab or panitumumab monoclonal antibodies is effective in a subset of colorectal cancers (CRCs), but the efficacy of these therapeutic agents can be limited due to the emergence of resistances. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain

Chromosome instability within lung cancer tumors increases the risk of recurrence or death and may help forecast recurrence long before standard tests, according to a study published online April 26 in the New England Journal of Medicine and Nature. In this study, tumor samples from 100 patients with non-small-cell lung cancer who had not previously

The U.S. Food and Drug Administration (FDA) has granted the accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). Keytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as microsatellite

On a recent study that analyzed patients between 17 and 93 years of age (N = 1592), who were participants in the ECOG-ACRIN trials, the influence of the most common monosomies (5, 7, and 17) within monosomal karyotype (MK+)/complex karyotype (CK+) acute myeloid leukemia (AML) was investigated. Most MK+ patients (93%) were found to be

In a retrospective study, researchers evaluated the impact of specific KRAS mutations among 392 patients with advanced and recurrent colorectal cancer. They detected KRAS mutation in 42.9% of tumors and found that KRAS mutation was predictive of overall survival (HR, 1.54; P = .005). Specifically, worse overall survival was associated with KRAS codon 12 mutations